Nov 2021: Ukuhlolwa kokuqala komtholampilo kwesizukulwane esilandelayo sesizukulwane esilandelayo se-chimeric antigen receptor T (CAR-T) cell therapy yaseNingizimu Korea, eklanyelwe ukugwema amasignali okuhlola amasosha omzimba, kusanda kuqala.
I-Korea Advanced Institute of Science and Technology (KAIST) imemezele ngoLwesithathu ukuthi ukuhlolwa komtholampilo kweSigaba 1b sokwelashwa kwayo ngamaseli e-CAR-T okwamanje kwenziwa e-Samsung Medical Center eSeoul. Ukuhlolwa kwenziwa neziguli zase-Korea eziyi-10 ezibuye zabuyela emuva futhi eziphikisayo zisakaza i-B cell lymphoma enkulu. Amalungelo okumaketha wepayipi adluliselwe enyuvesi ayiswa enkampanini iCurocell, eyasungulwa nguProfesa Kim Chan-hyuk. UCurocell uphethe uhlelo lokuthuthukiswa komtholampilo lwenguquko immunotherapy.
In addition, a Phase 2 isivivinyo somtholampilo involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for i-chimeric antigen receptor T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Ungahle uthande ukufunda: Ukwelashwa kwe-CAR T-Cell eKorea
Okutholwe kulolu cwaningo kwethulwe esihlokweni esanyatheliswa ku-inthanethi kumagazini ka-Okthoba we-Molecular Therapy.
